The forthcoming 2025 Annual Conference is scheduled to convene on May 10th at the Boston Marriott Cambridge. Following the success of the inaugural poster session, we are pleased to announce the continuation of this valuable component in our upcoming event. We extend an invitation for the submission of abstracts through our dedicated portal at https://lnkd.in/etc79cUw. The deadline for the submission is April 11, 2025. We welcome contributions covering a diverse range of topics of therapeutic antibodies. This encompasses, but is not restricted to, new modalities, innovative technologies in the discovery and development of antibody drugs, advancements in manufacturing, updates on clinical progress and data, as well as all topics related to therapeutic antibodies. Your participation and valuable insights will undoubtedly contribute to the enrichment of our conference proceedings. We look forward to receiving your insightful contributions and to fostering engaging discussions at the conference! If you have any further inquiries or questions, do not hesitate to contact us at [email protected]. You are also welcome to register for the annual conference via the following link: https://lnkd.in/efrshNfz
Chinese Antibody Society
生物技术研究
Cambridge，MA 17,566 位关注者
A nonprofit and non-governmental professional organization with focus upon therapeutic antibodies
关于我们
The Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. The mission of the society is to bring together industry, academics, healthcare providers, and investors to connect, communicate, and collaborate on the discovery, development, manufacturing, and marketing of therapeutic antibodies. Through its programs and services, the society serves as a nurturing platform to foster the productive interaction and networking among its members worldwide. The society, in collaboration with Oxford University Press, publishes its official journal, Antibody Therapeutics which is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7).
- 网站
-
https://chineseantibody.org/
Chinese Antibody Society的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Cambridge，MA
- 类型
- 非营利机构
- 创立
- 2016
- 领域
- Therapeutic Antibodies、Pharmaceuticals和Biotechnology
地点
-
主要
获取路线
US，MA，Cambridge，02319
Chinese Antibody Society员工
-
Yufang Shao
Welcome to Bon Opus, a CRO offering research reagents to the biotech community: our reagents, your discovery!
-
Jijie Gu, Ph.D.
President of Global Biologics Research & CSO & Global Head BD&L
-
Kevin (Guangbo) Liu
Director, CRO Business Development, Antibody Discovery, Antibody & Protein Engineering, Production, Analytics
-
Shawn Shouye Wang (王守业）
Business Enabling at WuXi XDC
动态
-
The proof of the new paper regarding antibody–drug conjugates formulation development was already published in Antibody Therapeutics with the title of “Fundamental Properties and Principal Areas of Focus in Antibody-Drug Conjugates Formulation Development”. This article comprehensively reviews and summarizes the formulations of commercial antibody-drug conjugates (ADCs) for the first time. The discussion extends to essential factors in drug product manufacturing and logistics processes. Additionally, the unique technical challenges of ADC formulation development compared to unconjugated antibody and the corresponding solutions are elucidated. All the seven co-authors of this paper are from WuXi XDC. Open access to this new paper at: https://lnkd.in/g_rpDQUg By the way, ADC is a key topic of our Chinese Antibody Society’s 2025 Annual Conference which will take place in Cambridge, MA, on May 10 (the day prior to 2025 PEGS conference). The theme of this conference is "New Frontiers in Bispecific Antibodies, Antibody-Drug Conjugates, and Beyond," Discover the conference registration and sponsorship opportunity at our society’s website: https://lnkd.in/efrshNfz. #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate #bispecific #bsab #bsabs #bispecificantibody #bispecificantibodies #annualconference
-
-
ADCs for autoimmune diseases: an insightful summary from DrugPatents-in-last-14days
# ADC for autoimmune diseases Autoimmune diseases have emerged as one of the most promising non-oncology indications for #ADC development. Traditional therapies often rely on systemic immunosuppression but these approaches are frequently associated with severe side effects and heightened infection risks. ADCs offer a novel approach to selectively eliminate pathogenic immune cells or modulate specific immune pathways, potentially offering safer and more effective treatments for autoimmune conditions. 1?? AbbVie’s ABBV-3373 was an ADC designed for the treatment of rheumatoid arthritis (RA). It linked #adalimumab with a glucocorticoid receptor modulator (GRM). 2?? BDCA2-ADC molecule by Duality Biologics causes a total suppression of IFNα production and broader inhibition of inflammatory cytokine production in human pDCs, whose uncontrolled production of IFN is crucial in pathogenesis of SLE. 3?? CD45-targeting ADC (Magenta Therapeutics, acquired by Dianthus Therapeutics, Inc. ). In models of multiple sclerosis, systemic sclerosis, and inflammatory arthritis, single-dose CD45-ADC treatment successfully achieved immune system “resetting.” 4?? LFD-200 (Lifordi Immunotherapeutics, Inc.), an ADC targeting VISTA. Preclinical data showed that LFD-200 has a short plasma half-life, prolonged immune cell residence time, and sustained immunosuppressive activity within target cells—while avoiding systemic toxicity typically associated with broad immune delivery. 5?? CD6-targeting ADC, in which MMAE was conjugated to an anti-CD6 monoclonal antibody. Although CD6 is present on all T cells, only activated T cells undergo rapid proliferation, making them more susceptible to the mitosis-inhibiting effects of MMAE. ?? One of the biggest challenges in applying ADCs to autoimmune diseases is target selection. Since many autoimmune conditions are systemic, identifying antigens highly expressed only on pathogenic immune cells is crucial to minimising off-target effects. Overall, although ADC applications in autoimmunity are still in early stages, their precision-targeting potential and mechanistic versatility offer exciting new possibilities for future therapeutic innovation.
-
-
We are thrilled to host 2025 Annual Conference at the Boston Marriott Cambridge in Cambridge, MA, on Saturday, May 10, 2025. In this event, Dr. Hongtao Lu, Co-Founder & CSO at Elpiscience Biopharmaceuticals, will present "Unlocking the potential of bi-specific myeloid engagers (BiME) in solid tumor immunotherapy". To register this event, please visit https://lnkd.in/efrshNfz Chinese Antibody Society members will enjoy discount on registration fees. To become a member, please visit https://lnkd.in/ejWM-qzq.
-
-
Chinese Antibody Society collaborated with SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia) again to co-organize ADC session during SAPA-GP’s 2025 Annual Conference in King of Prussia, PA. This ADC focused session with the theme of "Discovery & Development of Novel Antibody Drug Conjugates" was chaired by Dr. Shawn Shouye Wang, a member of the Chinese Antibody Society’s Board of Directors. This session was feathered with three distinguished speakers Dr. Jimmy Li , CEO of WuXi XDC, Dr. Dowdy Jackson, CEO of Jackson Consulting Group, LLC, and Dr. Xiao(Michelle) Meng, VP, Head of Global Regulatory Sciences of OBI Pharma, and covered ADC related key topics including the development of ADCs in industry, computational and machine Learning/AI, and ADC specific regulatory considerations. More information, refer to the post-conference report.
-
First ever dual payload ADC in the clinic by?Chengdu Kanghong Biotech! This exciting news was firstly posted at social media X by the ADC KOL, Dr. Raffaele Colombo. The company making this key milestone is a subsidiary of Chengdu Kanghong Pharmaceutical Group Co.,Ltd. in China. This drug, KH815 is a dual-payload ADC targeting TROP2 with two payloads, i.e., a topoisomerase I inhibitor(TOP1i) and an RNA polymerase II inhibitor(RNA POL IIi). The preclinical results of this ADC drug may be found from AACR's 2025 Annual Conference's abstract via the link below. https://lnkd.in/gXQPCAMZ By the way, ADC is a key topic of our Chinese Antibody Society’s 2025 Annual Conference which will take place in Cambridge, MA, on May 10 (the day prior to 2025 PEGS conference). The theme of this conference is "New Frontiers in Bispecific Antibodies, Antibody-Drug Conjugates, and Beyond," Discover the conference registration and sponsorship opportunity at our society’s website: https://lnkd.in/efrshNfz. #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate #bispecific #bsab #bsabs #bispecificantibody #bispecificantibodies #annualconference
-
We are thrilled to host 2025 Annual Conference at the Boston Marriott Cambridge in Cambridge, MA, on Saturday, May 10, 2025. In this event, Dr. Jie Chen, CTO of GV20 Therapeutics, will present "Industry Trending of Antibody-Drug Conjugates CMC Development and GV20 ADC development Strategy". To register this event, please visit https://lnkd.in/efrshNfz Chinese Antibody Society members will enjoy discount on registration fees. To become a member, please visit https://lnkd.in/ejWM-qzq.
-
-
Congratulations to GV20 Therapeutics and Mitsubishi Tanabe Pharma Corporation on their collaboration in ADC! Dr. Jie Chen, a seasoned CMC expert and Chief Technical Operations & Quality Officer at GV20 Therapeutics will give a presentation regarding ADC CMC at our society's 2025 annual conference. ADC is a key topic of our Chinese Antibody society’s 2025 Annual Conference which will take place in Cambridge, MA, on May 10 (the day prior to 2025 PEGS conference). The theme of this conference is "New Frontiers in Bispecific Antibodies, Antibody-Drug Conjugates, and Beyond," Discover the conference registration and sponsorship opportunity at our society’s website:? https://lnkd.in/efrshNfz.?
We are pleased to announce our collaboration with Mitsubishi Tanabe Pharma Corporation to develop potentially first-in-class antibody-drug conjugates. This collaboration underlines the strength of GV20’s STEAD platform in discovering novel tumor targets and human-derived antibodies. Read the full release: https://lnkd.in/ed9BbHJk #ADC#AI drug discovery#first-in-class
-
We highly recommend this new paper with the title of “177Lu-labeled antibody-drug conjugate: a dual mechanistic treatment modality in solid tumors”. The key conclusion from this paper is that the site-selectively 177Lu-labeled ADCs are effective in treating refractory tumors, including those with heterogeneous antigen expression, and warrant further exploration as a promising single-agent, dual-mechanistic treatment modality for solid tumors. The corresponding and first author of this paper is Aiko Yamaguchi at The University of Texas MD Anderson Cancer Center. By the way, ADC is a key topic of our Chinese Antibody Society’s 2025 Annual Conference which will take place in Cambridge, MA, on May 10 (the day prior to 2025 PEGS conference). The theme of this conference is "New Frontiers in Bispecific Antibodies, Antibody-Drug Conjugates, and Beyond," Discover the conference registration and sponsorship opportunity at our society’s website: https://lnkd.in/efrshNfz. #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate #bispecific #bsab #bsabs #bispecificantibody #bispecificantibodies #annualconference
-
AstraZeneca has established a global strategic collaboration with?Harbour BioMed. This partnership includes an option to license multiple programs leveraging?Harbour BioMed's proprietary?Harbour?Mice? fully human antibody technology platform across various therapeutic areas. Additionally, AstraZeneca has made a $105 million equity investment in?Harbour BioMed?BioMed. By the way,?bsAb?is a key topic of our?Chinese Antibody Society’s 2025 Annual Conference which will take place in Cambridge, MA, on May 10 (the day prior to 2025 PEGS conference). The theme of this conference is "New Frontiers in Bispecific Antibodies, Antibody-Drug Conjugates, and Beyond," Discover the conference registration and sponsorship opportunity at our society’s website:? https://lnkd.in/efrshNfz. #antibodies?#antibody?#antibodytherapeutics?#mabs?#mab?#antibodydiscovery #antibodydevelopment?#biologics https://lnkd.in/grnbakfx